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sTargeting the SASP to combat ageing:
Mitochondria as possible intracellular
allies?
Jodie Birch and Jo~ao F. Passos*Anti-senescence therapies, such as drugs that specifically kill senescent cells, to
stave off ageing are currently under investigation.While these interventions show
promise, their potential pitfalls are discussed herein. We have shown that the
mitochondria are essential for development of senescence and many of the
associated phenotypes, including the often detrimental senescence-associated
secretory phenotype (SASP). Here, we disentangle many ways in which the
mitochondriamay influence senescenceanddevelopmentof theSASPand focus
on possible pathways that could be exploited for future generation of anti-
senescence therapies with a clear aim; to specifically eliminate the problematic
features of senescent cells, while maintaining their beneficial characteristics.ageing; mitochondria; SASP; senescKeywords:ence; senolyticsIntroduction
Cellular senescence, the irreversible loss
of replicative potential in somatic cells,
was described over 50 years ago when it
was observed that normal human fibro-
blasts undergo a finite number of divi-
sions before ceasing to proliferate in
culture [1]. Thiswas subsequently termed
“replicative senescence” but we now
know that multiple stressors can cause.201600235
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License, which permits us
ided the original work is prosenescence, way before replicative ex-
haustion has taken hold, including oxi-
dative stress, chromatin modifications,
and oncogene activation [2]. Evidence
suggests that senescence is a potent anti-
cancer mechanism in vivo, preventing
cellular transformation [3]. However,
somehow paradoxically, senescent cells
are causally implicated in the ageing
process and in carcinogenesis in vivo.
With this double-edged swordatplay, it is
a major challenge to selectively target
senescent cells in order to inhibit their
deleterious effects, while preserving their
beneficial characteristics. This notion is
further compounded by recent reports
implicating senescence in other essential
biological processes, such as develop-
ment and wound healing [4, 5]. We have
recently demonstrated that clearance of
mitochondria inhibits thedevelopment of
many senescence-associated features,
while maintaining cell-cycle arrest [6].
While a current focus in the ageingfield is
to uncover therapies that are able towww. BioEssays Published by WILEY
nder the terms of the Creative
e, distribution and reproduction
perly cited.induce senescent cell death, specifically,
using drugs termed “senolytics”, we
propose that targeting key mitochondrial
pathways may hold more promise; effec-
tively manipulating the senescent phe-
notype to preserve only the beneficial
aspects, such as the tumor suppressive
cell-cycle arrest. Here, we highlight ways
by which the mitochondria could be
harnessed to alleviate senescence and
discuss the factors to consider when
targeting senescent cells in vivo.Senescence and ageing
TheactivationofaDNAdamageresponse
(DDR) is almost always a prerequisite
for cellular senescence, converging on
two main pathways: the p53-p21 and
p16INK4A-pRb tumor suppressor path-
ways, which establish andmaintain cell-
cycle arrest [3]. Over the past decade,
evidence implicating senescence in the
ageing process has mounted, with stud-
ies reporting age-related increases in
senescent cells in tissues from rodents
and primates [7–11]. Studies have also
indicated that senescence inducers, such
as telomeredysfunction andactivationof
pathways downstream of the DDR, can
accelerate the ageing process [12]. How-
ever, it is difficult to determine causality,
since other cellular responses, like apo-
ptosis, can be triggered by these stresses.
Only recently has a causal link between
senescence and the ageing process been
effectively demonstrated. Using a trans-
genic mouse model (INK-ATTAC), Baker
et al. found that elimination of p16ink4a-
positive senescent cells decreased the.bioessays-journal.com 1600235 (1 of 7)
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progeroid [13] and wild-type mice [14].
Similarly, using another mouse model,
elimination of naturally occurring
p19Arf-positive cells (another cell-cycle
inhibitor implicated in senescence) re-
stored lung compliance, structure, and
elasticity in aged mice [15]. Senescence
has been associated with chronic inflam-
matory diseases that are largely age-
related, including osteoarthritis (OA) [16]
and many respiratory diseases, such as
chronic obstructive pulmonary disease
(COPD) and bronchiectasis [7, 17]. More
recently, senescence was causally impli-
cated in disease development, when
transplantation of senescent cells into
the knee joints of mice induced an OA-
like-phenotype [18]. How senescent cells
contribute to ageing and disease devel-
opment in vivo is of great interest, with
the most plausible explanation residing
in the pro-inflammatory mediators they
release, including cytokines, chemo-
kines, and proteases; the so-called
senescence-associated secretory pheno-
type (SASP) [19]. The SASP has both
autocrine and paracrine effects, reinforc-
ing senescence and inducing senescence
in nearby cells [20, 21]. Furthermore,
evidence suggests that the SASP can
signal the immune system for senescent
cell clearance, whichmay become defec-
tive with age, leading to amplified
inflammatory responses and develop-
ment of chronic inflammatory disease
[22, 23]. The SASP may also promote
tumorigenesis, by causingmicroenviron-
ments that favor survival and progres-
sion of neoplastic cells and by inducing
malignant phenotypes through para-
crine mechanisms [19, 24]. While
there is no direct evidence causally
implicating the SASP specifically
in the ageing process, a number of
studies have shown that inhibition
of the key transcriptional regulator
of the SASP (NF-kB), improves
lifespan and health span during age-
ing [25–28]. Therefore, these studies
suggest that the SASP could be a
potential target for anti-ageing therapies.Mitochondria are
necessary for senescence
It has been thought for some time
that mitochondria are important for
senescence with studies showing that1600235 (2 of 7) Biomitochondrial-derived reactive oxygen
species (ROS) are involved in induction
and maintenance of senescence through
feedback loops replenishing the DDR
[29, 30]. Furthermore, mitochondrial
dysfunction has been shown to generate
single-strand breaks in telomere regions,
whichcontributes totelomereshortening,
culminating in senescence [30, 31]. Re-
cently, mitochondrial dysfunction was
shown to induce a distinct type of
senescence termed MiDAS (mitochon-
drialdysfunction-associatedsenescence),
and in mice with a deficiency in the
mitochondrial DNA (mtDNA) polymerase
PolG that causes increased mtDNA
mutations with age, senescent cells
accumulate [32]. Experimentally, it is
difficult to dissect the mitochondria-
associated processes that could contrib-
ute to senescence. Firstly, mitochondria
are sophisticated organelles, housing a
myriad of chemical reactions necessary
for metabolism and energy production.
Secondly, it is well established that any
perturbation of mitochondrial function
may result in adaptive mechanisms that
feedback into senescence-inducing path-
ways, subsequently affecting establish-
ment of causality. Thirdly, analysis of
mitochondrial function often relies on
isolation of mitochondria and assess-
ments in artificial environments. Finally,
measuring ROS in live-cells and in tissues
is technicallyverychallenging.Therefore,
we recently designed a proof-of-principle
experiment, which interrogated whether
mitochondria are truly necessary for
senescence [6]. Utilizing Parkin-mediated
mitophagy to completely remove mito-
chondria upon their depolarization,
we found that following a variety of
senescence triggers (e.g. oxidative stress
and oncogene activation) features of
cellular senescence, including the SASP,
were suppressed [6]. Paradoxically,
despite decreases in p21 and p16, mito-
chondrial clearance did not rescue
cell-cycle arrest, suggesting that mito-
chondria are key to the regulation of pro-
inflammatory features of senescent cells
and may be promising targets for anti-
SASP therapies.Regulating the SASP:
A role for mitochondria?
Recently, several mitochondrial pro-
cesses have been implicated in theessays 39, 5, 1600235, 2017 The Authors. Bioregulation of pro-inflammatory pheno-
types. However, these processes are
poorly investigated in cellular senescence
and while there are many potential path-
ways driving the SASP (Fig. 1), there is
much still to be elucidated. The positive
feedback loop linking mitochondrial-
derived ROS to persistent DDR signaling
“locks”cells ina senescent stateand leads
to development of senescence-associated
phenotypes, including the SASP [29].
Moreover, persistence of a DDR has been
shown to contribute to the SASP since
inhibition of the ATM kinase, a key
initiator of the DDR, suppresses the
SASP [33]. Mechanistically, ATM activates
NEMO which then activates the IKK
complex resulting in nuclear transloca-
tion of NF-kB, the major factor regulating
transcription of many SASP-associated
components [34].
mTOR and mitochondrial
crosstalk in SASP regulation
The mechanistic target of rapamycin
(mTOR) is a serine threonine kinase
believed to be particularly important to
the ageing process, since inhibition
with rapamycin extends lifespan and
healthspan in a range of model organ-
isms [35, 36]. mTOR signaling has been
implicated in both regulation of mito-
chondrial homeostasis and the SASP.
We have recently identified a novel
pathway linking the DDRwith increased
mitochondrial biogenesis through tran-
scriptional activation of PGC1-b, a
mitochondrial biogenesis regulator [6].
We found that activation of ATM
resulted in activation of AKT and mTOR
complex 1 (mTORC1), leading to PGC1-b-
dependent mitochondrial biogenesis
and ROS production, maintaining per-
sistent activation of the DDR and
stabilizing the SASP. mTOR inhibition
resulted in decreased mitochondrial
content in both senescent human and
mouse cells. Furthermore, it reduced
ROS and activation of a DDR, consistent
with the concept that ROSmaintains the
DDR during senescence [6]. Interest-
ingly, mTOR inhibition and lentiviral
mediated knock-down of PGC1-b, de-
spite reducing other features of senes-
cence in human fibroblasts, did not
rescue the cell-cycle [6]. Additionally,
mTOR can directly regulate the expres-
sion of SASP factors at the mRNA and
protein levels, independently of theEssays Published by WILEY Periodicals, Inc.
Figure 1. Possible mechanisms whereby mitochondria can impact on the senescence-
associated secretory phenotype. There are many ways in which mitochondria could influence
the development of the senescence-associated secretory phenotype (SASP). A positive
feedback loop between the DNA damage response (DDR) and the mechanistic target of
rapamycin (mTOR)-mediated mitochondrial biogenesis has been described, whereby
mitochondrial-derived reactive oxygen species (ROS) replenish DNA damage foci and DDR
signaling following initial senescence-inducing stimuli. This is mediated by the mitochondrial
biogenesis factor PGC1-b and involves the DNA damage response kinase ATM and AKT.
Persistent DDR signaling leads to senescence induction and development of the SASP. ATM
can also impact directly on the SASP via phosphorylation and activation of NEMO, which
then activates the IKK complex resulting in nuclear translocation of NF-kB, the major factor
regulating transcription of many SASP-associated components. mTOR can also directly
affect the SASP by controlling factors that stabilise mRNA transcripts and through influencing
translation of early SASP factors that modulate NF-kB activity. Shifts in metabolite status,
such as low NADþ/NADH and increases in AMP:ATP and ADP:ATP ratios, impact on the
SASP indirectly through other modulators of NF-kB activity. Sirtuins require NADþ as a
cofactor and are inhibitors of NF-kB activity and maintain transcriptionally silent chromatin,
regulating gene expression of many SASP factors. Similarly, poly-ADP ribose polymerases
(PARPs), such as PARP1, require NADþ as a donor of ADP-ribose, required for DNA repair
following genotoxic stress. Thus low NADþ leads to senescence induction and SASP
development. AMP-activated protein kinase (AMPK) is activated by high AMP and ADP levels
and can influence the SASP by activation of p53 and by stabilising p21 and p16 mRNA,
ultimately resulting in senescence and development of the SASP.
..... Insights & Perspectives J. Birch and J. F. Passos
Id
e
a
s
&
S
p
e
c
u
la
tio
n
smitochondria and DDR. For instance,
mTOR has been shown to regulate the
translation of MAPKAPK2 kinase, which
phosphorylates and inhibits the RNABioessays 39, 5, 1600235, 2017 The Authorsbinding protein ZFP36L1 during senes-
cence, limiting its ability to degrade
mRNA transcripts of numerous SASP
factors [37]. mTOR also promotes. BioEssays Published by WILEY Periodicals, Inctranslation of certain early SASP factors,
including IL-1a, which is a membrane
bound cytokine that can promote activ-
ity of NF-kB [26].
Mitochondrial metabolism in
SASP regulation
Senescent cells are metabolically ac-
tive but the role of metabolism in
cellular senescence is only recently
being uncovered, with studies suggest-
ing that the SASP is closely linked to
the metabolic state of the cell [38].
Glycolysis, which generates NADH and
pyruvate from glucose, ATP and NADþ
in the cytosol, is enhanced as cells
undergo replicative senescence [39]
and many transcripts of enzymes
involved in glycolysis are upregulated
during senescence [40]. Mechanisti-
cally, enhanced glycolysis may con-
tribute to development of senescent
phenotypes by impacting on p53, since
p53 acts to limit the glycolytic activity1600235 (3 of 7).
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pyruvate, which enters the mitochon-
drial matrix and feeds into the tricar-
boxylic acid (TCA) cycle as acetyl-
coenzyme A (acetyl-CoA) following
decarboxylation by pyruvate dehydro-
genase (PDH), may be important to
senescence induction, since supraphy-
siological levels reduce replicative life-
span of fibroblasts in vitro [42].
Additionally, in oncogene induced
senescence (OIS), PDH kinase 1 (an
inhibitor of PDH), is suppressed lead-
ing to enhanced usage of pyruvate in
the TCA cycle [43]. Low NADþ/NADH
ratios also promote senescence [38].
NADþ is required for poly-ADP ribose
polymerases (PARPs), the main
repairers of genotoxic stress-induced
damage, and inhibition of PARP-1
maintains DNA damage and sensitizes
cells to senescence in vitro [44]. More-
over, NADþ is a co-factor for sirtuins, a
family of histone and protein deacety-
lases. Sirtuins impact on senescence in
various ways, including regulating
NF-kB activity and in maintaining
transcriptionally silent chromatin of
NF-kB-dependent genes, such as SASP
factor transcripts [45]. Increases in
AMP:ATP and ADP:ATP ratios have
been linked to the senescence state.
AMP-activated protein kinase (AMPK)
is a regulator of cellular responses to
energy stress and is activated by
increased AMP and ADP, which then
regulates a series of responses includ-
ing mitochondrial biogenesis and glu-
cose uptake [46]. AMPK can also lead
to phosphorylation and activation of
p53, promoting cell-cycle arrest via
transcriptional upregulation of p21 [47]
and can inhibit Hu antigen R-depen-
dent degradation of p21 and p16
mRNA [48]. Additionally, a low
NADþ/NADH ratio leading to AMPK
activation was proposed as a mecha-
nism mediating MiDAS, with a distinct
SASP, in the aforementioned study [32].
Interestingly, macrophages activated
by pro-inflammatory stimuli undergo
metabolic reprogramming, whereby
mitochondria shift to a more glycolytic
state and produce ROS, promoting a
pro-inflammatory response [49], di-
rectly linking mitochondrial metabo-
lism to pro-inflammatory cellular
responses. The above studies suggest
that understanding metabolic control
of senescence and the SASP may be1600235 (4 of 7) Biocrucial for development of therapies
for age-related disease.
Mitochondrial DAMPs and the
SASP
An additional, more recently explored
mechanism by which mitochondria
may impact on the SASP involves
mitochondrial DNA (mtDNA). mtDNA
predominantly encodes components of
oxidative phosphorylation and con-
tains unmethylated CpG islands, simi-
lar to bacterial DNA [50]. Bacterial DNA
and other pathogenic stimuli, such as
viral RNA, can activate innate immune
receptors, known as pattern recogni-
tion receptors (PRRs). Similarly, com-
ponents released from cells during
damage, termed damage associated
molecular patterns (DAMPS) can
also activate PRRs. mtDNA is one such
immunostimulatory factor when pres-
ent outside of the mitochondrial ma-
trix [50]. Indeed, several signaling
pathways sense mtDNA in the cyto-
plasm, including the NLRP3 inflamma-
some, which converges on NF-kB [51]
and the cytosolic sensor of DNA: the
cGAS-STING pathway, which ulti-
mately leads to the expression of type
I interferon genes and an anti-viral
innate immune responses [52]. Inter-
estingly, exposure to cigarette smoke,
an inducer of senescence and the key
risk factor for COPD, causes mtDNA
release [53]. mtDNA may, therefore,
be important to development of pro-
inflammatory phenotypes, but its
role in senescence is unknown. The
SASP can be induced by activation of
cytosolic sensors, potentially indepen-
dently of mitochondria; innate immune
sensors IFI16 and AIM2 have been
shown to play a role in modulating
senescence [54]. The source of cytosolic
DNA during senescence is unclear but
it is possible that DNA may leak from
the nucleus  something described
during deep senescence [55].
Eliminating senescent
cells: Mitochondria, friend
or foe?
Although several pieces of evidence
suggested a role for senescence
during ageing in vivo, only recently
has senescence been uncovered asessays 39, 5, 1600235, 2017 The Authors. Bioan active contributor to the process
[13, 14]. These proof-of-principle ex-
periments led to the idea that one could
develop drugs to selectively kill senes-
cent cells. The current senolytics under
investigation work by targeting pro-
survival and anti-apoptotic pathways
specifically activated in senescent cells.
Dasatinib is a tyrosine kinase inhibitor
known to interfere with suppression of
apoptosis and quercetin is a flavonol
and inhibitor of phosphatidylinositol-
4,5-bisphosphate 3-kinases (PI3Ks) that
regulate multiple cellular functions,
including survival. When given in
combination (DþQ), they reduce se-
nescent cell burden in aged, radiation-
exposed and progeroid mice and
improve health span, including cardiac
function [56]. DþQ administration also
reduced senescent cell frequencies and
improved established age-associated
vascular phenotypes, such as aortic
calcification, in aged and hypercholes-
terolaemic mice [57]. Researchers have
shown that DþQ reduces expression of
BCL-xL (an anti-apoptotic protein from
the BCL-2 family) in both senescent pre-
adipocytes and HUVEC cells [56]. Inhib-
itors of the BCL-2 family are also
senolytic in vitro, such as navitoclax
(ABT-263) [58]. Navitoclax effectively
depletes senescent cells, including
senescent bone marrow hematopoietic
stem cells and senescent muscle stem
cells, in sub-lethally irradiated and
physiologically aged mice [59]. BCL-2
family members act upstream of
mitochondrial-dependent apoptosis,
protecting mitochondrial outer mem-
brane integrity by binding to the
pro-apoptotic Bax and Bak, which
permeabilize the mitochondrial outer
membrane, leading to release of cyto-
chrome C, caspase activation, and
rapid cell death [60].
Nevertheless, there are potential
downsides to utilizing therapies target-
ing anti-apoptotic mechanisms. Re-
cently, it was described that BH3
mimetics could activate a process
known as incomplete mitochondrial
outer membrane permeabilization
(MOMP) [61]. This type of MOMP
has been designated “minority MOMP”
(miMOMP) since only a minor portion
of the mitochondria within the
cell undergo MOMP following a
sub-lethal stress. miMOMP causes lim-
ited caspase activation, which isEssays Published by WILEY Periodicals, Inc.
Figure 2. miMOMP: potential side effects of senolytics. Senescent cells overexpress anti-
apoptotic proteins such as BCL-2 family members, which protect mitochondrial outer
membrane integrity by binding to the pro-apoptotic BCL-2 members: Bax and Bak. Many of
the current senolytic drugs under investigation work by inhibiting these anti-apoptotic
proteins, leading to mitochondrial outer membrane permeabilization (MOMP), cytochrome C
release, widespread activation of caspases and ultimately apoptosis. In young cells that do
not overexpress anti-apoptotic factors, inhibitors of these proteins are known to induce
minority MOMP (miMOMP), whereby a small portion of the mitochondria in the cell undergo
MOMP, leading to cytochrome C release and limited caspase activation. While this level of
caspase activity is not sufficient to induce apoptosis, increased DNA damage can occur,
which could potentially lead to genomic instability and cancer. It is also possible that
caspase-induced DNA damage can cause premature senescence and accelerated ageing in
neighboring non-senescent cells.
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leads to caspase-dependent DNA dam-
age and genomic instability, promoting
tumorigenesis [61]. miMOMP could well
be a relevant “side effect” of senolytic
drugs, such as the BCL-2 inhibitors,
that should be explored. While these
senolytics selectively kill senescent
cells, the long-term effects on young
tissues have not yet been adequately
investigated. It could be that miMOMP
induction in healthy neighboring
cells causes genomic instability,
leading to tumorigenesis or possibly
accelerated ageing due to caspase-
dependent DNA damage (Fig. 2). ABioessays 39, 5, 1600235, 2017 The Authorsbetter approach may be to target
mitochondrial homeostasis and metab-
olism to specifically suppress the SASP.
To generate therapeutics with specific
effects on the SASP, the metabolomic
networks involved, such as glycolysis,
AMPK activation and NADþ sensing
need to be further elucidated in senes-
cence. Experiments are needed to
determine what components of these
pathways are of particular importance
and how inhibiting or augmenting
certain aspects would fare in young,
healthy cells, in addition to how they
may suppress senescence-associated
inflammation.. BioEssays Published by WILEY Periodicals, IncConclusions and
prospects
The SASP may be a key target for anti-
ageing therapies. However, given the
complexity of functions occurring
within mitochondria, we are still igno-
rant as to what factors can be targeted
in order to counteract the SASP. Our
experiments revealed a key role for
mitochondria in SASP regulation but
more work is needed to identify specific
targets for interventions that are able to
suppress the SASP, while maintaining
cell-cycle arrest. Anti-oxidants have
been shown to suppress the DDR, but
may not be the most adequate, since
they may allow cell-cycle progres-
sion [62]. Other interventions such as
mTOR inhibition offer better promise,
particularly since they reduce ROS and
the DDR, but do not allow cell-cycle
progression. However, mTOR inhibi-
tors, particularly rapamycin, may not
be adequate for use in the clinic since
they have many negative side-effects.
Moreover, if senolytics or SASP
suppressors are to be used in the clinic,1600235 (5 of 7).
J. Birch and J. F. Passos Insights & Perspectives.....
Id
e
a
s
&
S
p
e
c
u
la
ti
o
n
sthe timing of interventions needs to be
carefully calculated given that senes-
cence may have beneficial functions
early on. The reliance on inhibition of
anti-apoptotic proteins to kill senescent
cells may result in sub-lethal caspase
activity that may induce unwanted
DNA damage, the consequences of
which should be fully investigated. A
better approach may be to target
specifically pathways regulating the
SASP. Nevertheless, targeting the SASP
and its regulatory pathways as a
therapeutic approach needs careful
consideration, particularly since the
SASP has been involved in beneficial
effects such as immune clearance of
senescent cells and wound healing.
Future anti-ageing strategies need to
impact on the negative aspects of the
SASP, while maintaining its positive
roles. However, in order to do this, we
require further understanding of the
SASP regulatory mechanisms and its
role in different cell types and tissues
during organismal ageing.Acknowledgments
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